SWM
RKDA icon

SeaCrest Wealth Management’s Arcadia Biosciences RKDA Stock Holding History

SeaCrest Wealth Management’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11
Closed -$3K – 1572
2019
Q1 		$3K Hold
11
– – ﹤0.01% 1863
2018
Q4 		$1K Hold
11
– – ﹤0.01% 2055
2018
Q3 		$2K Hold
11
– – ﹤0.01% 2082
2018
Q2 		$4K Buy
11
+10
+1,000% +$5.46K ﹤0.01% 1886
2018
Q1 		$1K Hold
1
– – ﹤0.01% 2120
2017
Q4 		$0 Buy
+1
New +$217 ﹤0.01% 2242

Other funds holding RKDA

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

SeaCrest Wealth Management's RKDA Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Arcadia Biosciences (RKDA) in Q2 2019, closing a stake of 11 shares — an estimated $3K sold.

SeaCrest Wealth Management first reported a position in RKDA in Q4 2017 and held it in 6 quarters. The position peaked at $4K in Q2 2018. 14 funds tracked by Wall St. Rank hold RKDA as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining Arcadia Biosciences position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 11 Arcadia Biosciences shares in Q2 2019, an estimated $3K.
  • SeaCrest Wealth Management first reported a position in Arcadia Biosciences in Q4 2017 and held it in 6 quarters.
  • SeaCrest Wealth Management's Arcadia Biosciences position peaked at $4K in Q2 2018.
  • 14 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.